# 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

> **NCT02057445** · PHASE1 · COMPLETED · sponsor: **New York Medical College** · enrollment: 1 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma
- Hodgkins Lymphoma
- Lymphoproliferative Disorder

## Interventions

- **DRUG:** EBV CTL's
- **OTHER:** Peripheral Blood Donor

## Key facts

- **NCT ID:** NCT02057445
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-12-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057445, "3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02057445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*